JC Medical Announces First U.S. Treatment With J-Valve TAVR Device (Dr. John Webb)
JC Medical announced the successful treatment of the first U.S. patient with the company’s transfemoral transcatheter aortic valve replacement (TAVR) device, the J-Valve TF System. The patient was treated at The Christ Hospital – Cincinnati, Ohio by Dean Kereiakes, M.D., FACC, FSCAI, medical co-director of the Lindner Research Center, working with Joseph Choo, M.D., and Geoffrey Answini, M.D.
The U.S. Food and Drug Administration (FDA) approved the use of the J-Valve for patients with aortic regurgitation through the agency’s expanded access (“compassionate use”) regulatory pathway.
The world’s first J-Valve TF implant was performed earlier this year by John Webb, M.D., and Jian Ye, M.D., MSc, FRCSC at St. Paul’s Hospital in Vancouver, Canada. This case was recently published online ahead of print in EuroIntervention.
Read the full story here.
Story also found on Cath Lab Digest.
Providence in the Park Volunteer